DB
JBIO

Dmitry Balyasny’s Jade Biosciences JBIO Stock Holding History

Dmitry Balyasny’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.5M Buy
878,726
+476,237
+118% +$9.93M 0.02% 722
2026
Q1 		$5.65M Buy
+402,489
New +$5.83M 0.01% 1319
2024
Q4 		– Sell
-292
Closed -$21.4K – 2721
2024
Q3 		$21.4K Buy
+292
New +$18.8K ﹤0.01% 2662

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dmitry Balyasny's JBIO Position: Q2 2026 in Review

Dmitry Balyasny increased its Jade Biosciences (JBIO) stake by 118% in Q2 2026, buying an estimated $9.93M and bringing the position to 878,726 shares worth $19.5M. The position accounts for 0.02% of the portfolio, ranked #722.

Dmitry Balyasny first reported a position in JBIO in Q3 2024 and has held it in 3 quarters since. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Dmitry Balyasny held 878,726 shares of Jade Biosciences worth $19.5M as of Q2 2026.
  • Dmitry Balyasny bought 476,237 Jade Biosciences shares in Q2 2026, an estimated $9.93M.
  • Jade Biosciences made up 0.02% of Dmitry Balyasny's portfolio in Q2 2026, its #722 holding.
  • Dmitry Balyasny first reported a position in Jade Biosciences in Q3 2024 and has held it in 3 quarters since.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.